Page 35 - Read Online

Yagishita et al. J Cancer Metastasis Treat 2019;5:75 Journal of Cancer
DOI: 10.20517/2394-4722.2019.026 Metastasis and Treatment

Review Open Access

Monoclonal antibody pharmacogenomics in cancer
treatment

Shigehiro Yagishita, Akinobu Hamada

Division of Molecular Pharmacology, National Cancer Center Research Institute, Chuo-ku, Tokyo 104-0045, Japan.
Correspondence to: Dr. Shigehiro Yagishita, Division of Molecular Pharmacology, National Cancer Center Research Institute,
5-1-1, Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. E-mail: syagishi@ncc.go.jp

How to cite this article: Yagishita S, Hamada A. Monoclonal antibody pharmacogenomics in cancer treatment. J Cancer
Metastasis Treat 2019;5:75. http://dx.doi.org/10.20517/2394-4722.2019.026

Received: 26 Aug 2019 First Decision: 8 Oct 2019 Revised: 16 Oct 2019 Accepted: 5 Nov 2019 Published: 11 Nov 2019

Science Editor: Godefridus J. Peters Copy Editor: Cai-Hong Wang Production Editor: Tian Zhang

Abstract
Conventionally, in the pharmacokinetic/pharmacodynamic analysis of small molecule compounds such as
cytotoxic anticancer drugs, polymorphism analysis of genes related to absorption, distribution, metabolism,
and excretion has been performed in addition to the analyses of blood concentrations of drugs. Such
pharmacogenetic factors play an important role in predicting therapeutic effects and adverse events and in the
proper use of drugs. With the recent launch of immune checkpoint inhibitors (ICIs) and the rapid development
of antibody-drug conjugates (ADCs) currently underway, there is no doubt that antibody drugs, which are large
molecule compounds, will become key drugs in anticancer drug treatment. However, the pharmacokinetic
and pharmacodynamic analysis of antibody drugs is still not sufficient, and further elucidation of factors and
mechanisms affecting their dynamics in the human body is necessary. Moreover, the pharmacogenomic factors
of antibody drugs have not yet been fully studied. There are many factors that should be clarified, such as factors
that regulate the host immune response in ICI therapy and the effects of ATP-binding cassette transporter and
cytochrome P450 on the payload of ADCs. This review provides an outline of antibody drugs in cancer treatment
and summarizes the pharmacogenomic factors of antibody drugs known to date.

Keywords: Pharmacogenomics, antibody drug, antibody-dependent cellular cytotoxicity, immune checkpoint
inhibitor, antibody-drug conjugate

© The Author(s) 2019. Open Access This article is licensed under a Creative Commons Attribution 4.0
International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long
as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license,
and indicate if changes were made.

www.jcmtjournal.com